LONDON, July 26, 2011 /PRNewswire/ --
UK pharma group GlaxoSmithKline reports a 2% sales dip in the second quarter but highlights strong underlying sales momentum.
In an interview with financial broadcaster http://www.cantos.com, CEO Andrew Witty and CFO Simon Dingemans review Q2 results including overall delivery of strategy, declining "headwinds", R&D strategy, improving margins and a review of the recently implemented Drug Performance Units.
The interview and transcript are available now on http://www.cantos.com/company/GlaxoSmithKline.
Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email email@example.com or phone +44-207-936-1352.